Takeda Pharmaceutical Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Christophe Weber

Chief Executive Officer (CEO)

JP¥1.7b

Compensación total

Porcentaje del salario del CEO	17.1%
Permanencia del CEO	10yrs
Participación del CEO	0.04%
Permanencia media de la dirección	9.7yrs
Promedio de permanencia en la Junta Directiva	6.7yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Christophe Weber en comparación con los beneficios de Takeda Pharmaceutical?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	JP¥144b
Dec 31 2023	n/a	n/a	JP¥178b
Sep 30 2023	n/a	n/a	JP¥192b
Jun 30 2023	n/a	n/a	JP¥301b
Mar 31 2023	JP¥2b	JP¥295m	JP¥317b
Dec 31 2022	n/a	n/a	JP¥275b
Sep 30 2022	n/a	n/a	JP¥213b
Jun 30 2022	n/a	n/a	JP¥197b
Mar 31 2022	JP¥2b	JP¥281m	JP¥230b
Dec 31 2021	n/a	n/a	JP¥439b
Sep 30 2021	n/a	n/a	JP¥473b
Jun 30 2021	n/a	n/a	JP¥431b
Mar 31 2021	JP¥2b	JP¥267m	JP¥376b
Dec 31 2020	n/a	n/a	JP¥181b
Sep 30 2020	n/a	n/a	JP¥56b
Jun 30 2020	n/a	n/a	JP¥120b
Mar 31 2020	JP¥2b	JP¥273m	JP¥44b
Dec 31 2019	n/a	n/a	JP¥13b
Sep 30 2019	n/a	n/a	JP¥83b
Jun 30 2019	n/a	n/a	JP¥64b
Mar 31 2019	JP¥2b	JP¥269m	JP¥135b
Dec 31 2018	n/a	n/a	JP¥110b
Sep 30 2018	n/a	n/a	JP¥141b
Jun 30 2018	n/a	n/a	JP¥120b
Mar 31 2018	JP¥1b	JP¥254m	JP¥187b

Compensación vs. Mercado: La compensación total de Christophe($USD11.13M) está por encima de la media de empresas de tamaño similar en el mercado BR ($USD6.07M).

Compensación vs. Ingresos: La compensación de Christophe ha sido consistente con los resultados de la empresa en el último año.

CEO

Christophe Weber (58 yo)

10yrs

Permanencia

JP¥1,723,000,000

Compensación

Mr. Christophe Weber has been the President and Chief Executive Officer of Takeda Pharmaceutical Company Limited since June 27, 2014 and April 2015 respectively and served as its Chief Operating Officer fr...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Christophe Weber	President	10yrs	JP¥1.72b	0.040% ¥ 90.3m
Andrew S. Plump	President of Research & Development and Representative Director	no data	JP¥972.00m	0.0035% ¥ 8.0m
Seigo Izumo	Chair of Management Board	no data	sin datos	sin datos
Milano Furuta	Chief Financial Officer	less than a year	sin datos	sin datos
Haruhiko Hirate	Member of Management Board	no data	sin datos	sin datos
Salvatore Alesci	Member of Management Board and Head of R&D Global Science & Biomedical Policy	no data	sin datos	sin datos
Norimasa Takeda	Chief Accounting Officer & Corporate Controller	no data	sin datos	sin datos
Iwaaki Taniguchi	Senior Vice President of Corporate Finance & Controlling Department	11.3yrs	sin datos	sin datos
Gabriele Ricci	Chief Data & Technology Officer	2.3yrs	sin datos	sin datos
Christopher David O'Reilly	Global Head of Investor Relations & Global Finance	3.8yrs	sin datos	sin datos
Yoshihiro Nakagawa	Global General Counsel	9.7yrs	sin datos	sin datos
Mwana Lugogo	Chief Ethics & Compliance Officer	9.7yrs	sin datos	sin datos

9.7yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de TAKP34 es experimentado (9.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Christophe Weber	President	10yrs	JP¥1.72b	0.040% ¥ 90.3m
Andrew S. Plump	President of Research & Development and Representative Director	9yrs	JP¥972.00m	0.0035% ¥ 8.0m
John M. Maraganore	Independent External Director	2yrs	JP¥32.00m	sin datos
Steven S. Gillis	Independent External Director	5.4yrs	JP¥38.00m	0.00026% ¥ 586.4k
Emiko Higashi	Independent External Director	8yrs	JP¥43.00m	sin datos
Yoshiaki Fujimori	Independent External Director	8yrs	JP¥41.00m	0.00057% ¥ 1.3m
Ian T. Clark	Independent External Director	5.4yrs	JP¥38.00m	0.000070% ¥ 157.9k
Jean-Luc Butel	Independent External Director	5yrs	JP¥38.00m	sin datos
Michel Orsinger	Independent External Director	8yrs	JP¥39.00m	sin datos
Masami Iijima	Independent External Chair	3yrs	JP¥43.00m	sin datos
Koji Hatsukawa	Independent External Director	8yrs	JP¥43.00m	0.00041% ¥ 924.8k
Constantine Saroukos	Representative Director	5yrs	JP¥690.00m	sin datos

6.7yrs

Permanencia media

66.5yo

Promedio de edad

Junta con experiencia: La junta directiva de TAKP34 se considera experimentada (6.5 años de antigüedad promedio).

Takeda Pharmaceutical Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Takeda Pharmaceutical Company Limited Announces Demise of its Board Member, Olivier Bohuon

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

Takeda Pharmaceutical Company Limited Announces Chief Financial Officer Succession, Effective April 1, 2024

Takeda Pharmaceutical Company Limited Announces Board Changes

Recent updates

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Pharmaceutical Company Limited Announces Demise of its Board Member, Olivier Bohuon

Takeda Receives Positive Chmp Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

U.S. Food and Drug Administration Approves Subcutaneous Administration of Takeda Pharmaceutical Company Limited's ENTYVIO (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease

Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (Tak-079), A Potential Best-In-Class Anti-Cd38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

FDA Approves Takeda's EOHILIA (budesonide Oral Suspension)

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024

Takeda Pharmaceutical Company Limited Announces Chief Financial Officer Succession, Effective April 1, 2024

Takeda's Gammard Liquidid®? Approves by U.S. Fda for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

Takeda Announces U.S. Food and Drug Administration Approves Hyqvia® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]

Takeda Pharmaceutical Company Limited to Report Q2, 2025 Results on Oct 31, 2024

Takeda Receives Positive Chmp Opinion for Hyqvia as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

The European Commission Approves Label Update for Takhzyro®? (Lanadelumab), Expanding Its Use to A Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (Hae)

U.S. Fda Approves Takeda's Adzynma (Adamts13, Recombinant-Krhn) as the First and Only Recombinant Adamts13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombotic Thrombocytopenic Purpura

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Takeda Pharmaceutical Company Limited Announces Late-Breaking Data from Phase 2B Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis At American College of Rheumatology Convergence Annual Meeting

Takeda Pharmaceutical Company Limited Revises Earnings Guidance for the Fiscal Year Ending March 31, 2024

Takeda Pharmaceutical Company Limited Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on December 1, 2023 and Provides Year-End Dividend Guidance for the Year Ending March 31, 2024

Takeda Pharmaceutical Company Limited Announces European Commission Approves ADCETRIS (Brentuximab Vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

Takeda Pharmaceutical Company Limited Announces Phase 3 ADMIRE-CD II Study

Takeda Pharmaceutical Company Limited to Report Q3, 2024 Results on Feb 01, 2024

Takeda Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

Takeda Pharmaceutical Company Limited Announces U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

Takeda Announces Approval of CUVITRU Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema in Patients Aged 2 Years and Older

Takeda Announces FDA Acceptance of NDA Resubmission of Tak-721 (Budesonide Oral Suspension) for the Short-Term Treatment of Eosinophilic Esophagitis

Takeda Pharmaceutical Company Limited Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a highly selective oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Takeda Pharmaceutical Company Limited Announces Board Changes

Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

Takeda Pharmaceutical Company and Eli Lilly and Company Provides Update on Class Action

Takeda Pharmaceutical Company Limited Proposes Dividend

Takeda Pharmaceutical Company Limited to Report Q2, 2024 Results on Oct 26, 2023

Takeda Announces S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Takeda Pharmaceutical Company Limited Provides Dividend Guidance for the Fiscal Year 2023

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

Takeda Pharmaceutical Company Limited Announces FDA Approves the Supplemental Biologics License Application for the Expanded Use of TAKHZYRO

Takeda Pharmaceutical Company Limited Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Takeda Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on May 11, 2023

Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC

Arrowhead Pharmaceuticals Inc. and Takeda Pharmaceutical Company Limited Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Takeda Pharmaceutical Company Limited Announces Favorable Phase 3 Safety and Efficacy Results of TAK-755 as Compared to Standard of Care in Congenital Thrombotic Thrombocytopenic Purpura

Takeda’S Phase 3 Aurora Study Provides Evidence of Maribavir’S Clinically Meaningful and Durable Effect in Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Patients, Despite Missing Primary Endpoint

Takeda's Qdenga(R) Dengue Tetravalent Vaccine [Live, Attenuated]) Approves for Use in European Union

Takeda Pharmaceutical Company Limited Announces the U.S. Food and Drug Administration Accept and Grant Priority Review of the Biologics License Application for TAK-003

Takeda Announces Phase 3 Trial of Iclusig (Ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, Setting with No Targeted Treatments Approved in the US

Takeda Announces European Commission Approves LIVTENCITY (Maribavir) for Treatment of Adults with Post-Transplant Cytomegalovirus Infection and/or Disease that are Refractory (with or without Resistance) to One or More Prior Therapies

Takeda Pharmaceutical Company Limited to Report Q3, 2023 Results on Feb 02, 2023

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad